BHCM
AVBP icon

Brevan Howard Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Brevan Howard Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,635
Closed -$335K – 2558
2025
Q4 		$335K Buy
+16,635
New +$346K ﹤0.01% 1312
2025
Q3 		– Sell
-9,592
Closed -$209K – 2343
2025
Q2 		$209K Buy
+9,592
New +$199K ﹤0.01% 1695

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Brevan Howard Capital Management's AVBP Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 16,635 shares — an estimated $335K sold.

Brevan Howard Capital Management first reported a position in AVBP in Q2 2025 and held it in 2 quarters. The position peaked at $335K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 16,635 ArriVent BioPharma shares in Q1 2026, an estimated $335K.
  • Brevan Howard Capital Management first reported a position in ArriVent BioPharma in Q2 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's ArriVent BioPharma position peaked at $335K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.